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A study has been done on the biopharmaceutical properties of antihypertensive drug 
products marketed in Jamaica. Four pharmacological classes of antihypertensive drugs were 
selected: Beta blocker (Atenolol), Angiotensine Converting Enzyme inhibitors (ACEI), Diuretics 
and Central Alpha Blocker (Methyldopa). 
Products were tested for uniformity of weight, content of active ingredients (assay) and 
dissolution rates, following the British Pharmacopoeia/USP procedures. 
It was observed that products contained the required level of active ingredients. However, some 
products make the active ingredient available for absorption faster and to a greater extend than 
others. 
Results generally suggest that more than company reputation and cost is required for making 
rational decisions on drug product selection. 
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1. Introduction 
Hypertension is one of the major chronic illnesses in Jamaica, and is included in the top six 
reasons for visits to primary care facilities. In 2002, hypertension was the leading cause for 
medical visit to primary health care facilities. The high incidence these disease in Jamaica has 
lead to a continued demand for products used in its management (1). However, inadequate 
patients' outcomes seem to have been fraught by problems arising from poor compliance, 
discontinuation and switching between therapies all of which may be economically motivated (2). 
In addition, patients are often on multiple drug therapies for these conditions as they are 
sometimes not well controlled on monotherapy. Since a significant difference may sometimes 
exist between the prices of brand and their generic analogues, drug product selection which 
minimizes cost while maximizing safety and efficacy continues to be a primary and challenging 
responsibility of pharmacists (1) 
In order for a drug to be interchangeable with the innovator's brand, it must be pharmaceutically 
equivalent and bioequivalent (1) 
According to the United States Food and Drug Administration (FDA), drug products are 
considered to be pharmaceutical equivalents if they contain the same active ingredient(s), are of 
the same dosage form, route of administration, and are identical in strength or concentration (3) 
The term bioequivalence describes the bioavailability of two or more drug products 
(pharmaceutical equivalents) studied under similar experimental conditions. 
The rate and extent of absorption of the test drug must not show significant difference from the 
rate and extent of absorption of the reference drug product when administered at the same molar 
dose of therapeutic ingredient, under similar experimental conditions in either single or multiple 
doses. However, the difference in bioavailability of drug from the test and reference products 
may be intentional as is the case with the modified and targeted release drug delivery systems. 
These differences should be reflected in labeling and should not impede the attainment of 
effective drug concentration in the body on chronic use (3) 
Prior to the 1938 enactment of the Food Drug and Cosmetic Act (FDCA), regulatory barriers to 
generic drug competition did not exist. Generic drug companies could formulate, manufacture 
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and market their products without submitting bioequivalence or efficacy data to the FDA. In 
1938, the Act required that document the safety of the product to the FDA. This general 
recognition of safety was based on a history of safe use of the innovator product. In 1962, the 
Act was amended to add requirement of "substantial evidence of both safety and efficacy in 
adequate and well-controlled studies" Pre-1962 drugs were also evaluated. In 1970, the FDA 
established the Abbreviated New Drug Application to review the approval of generic versions of 
drug products approved between 1938 and 1962 (4). Potential generic drug manufacturers were 
notified of requirements for developing versions of approved drugs. This resulted in the 
Abbreviated New Drug Application (ANDA), for which approval by the FDA was based on 
active ingredients and bioequivalence, rather than safety and efficacy data (5) 
The ANDA does not require generic manufacturers to perform pre-clinical or clinical tests in 
order to establish safety and efficacy of active drug as this would have already been done by the 
innovator brand. The major requirement of an Abbreviated New Drug Application (ANDA) is 
the inclusion of bioequivalence evaluation, chemistry, and microbiologic evaluation, inspection 
of manufacturing facility and review of the proposed drug label (5) 
Bioavailability and bioequivalence problems are more likely to occur with solid oral dosage 
forms; therefore bioequivalence evaluation is a very important aspect of the ANDA review 
process (4) 
Under the Drug Price Competition and Patent Term Restoration act of 1984, manufacturers 
seeking approval to market a generic product are required to submit data showing that the drug 
product is bioequivalent to the innovator product. A major premise underlying the 1984 law is 
that bioequivalent drug products are therapeutically equivalent and thus interchangeable (3). The 
Approved Drug Products with Therapeutic Equivalence Evaluations guideline (the `Orange 
Book') (6) identifies drug products approved by the FDA as safe and effective. The book includes 
therapeutic equivalents for approved multi-source prescription drug products and is updated 
monthly. It cites a letter code for every multi-source product. The code indicates the FDA's 
evaluation regarding the therapeutic equivalence of the product with respect to the innovator's 
brand (5). 
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The main substantive requirement for approval of an ANDA by regulatory authorities in most 
countries is that the manufacturer of the generic product submits data demonstrating the 
bioequivalence of his product to the brand. One approach in the establishment of bioequivalence 
is through the demonstration of a clinically significant effect. This is usually done in the initial 
stages of product development when proving the efficacy of a new chemical entity. Another 
approach is through quantification of pharmacologic effect by correlating the intensity of 
response with drug concentration at the site of action. However, it is difficult to monitor 
pharmacologic data as precision and reproducibility are difficult to establish. Moreover, only a 
limited number of pharmacologic effects (viz blood pressure, heart rate, body temperature) 
amenable to such measurement are available in practice. 
The third and most commonly employed method involves measurement of drug concentration in 
the biological fluids. This study, which can adopt single of multiple dose assessment, require 
the administration of specified dosage amount to a group of normal healthy adults usually of 
ages 18 to 35 years. Blood and/or urine samples are then collected at specified time interval, 
samples are analyzed and used to make inferences on the rate and extent of absorption 
(bioavailability) of the product. 
Currently, the Food and Drug Administration (FDA) requires that the innovator and test product 
differ in terms of their rate and extent of absorption by a value of not more than 20 to 25 %(7). In 
Jamaica, there are regulations that govern the importation of drugs and pharmaceuticals. Drug 
approval for distribution is based on evidence of safety, efficacy and pharmaceutical quality 
submitted by the distributors as being representative of approval document at country of origin. 
The procedure involves the review of the scientific data that are submitted. In addition, for 
generic drug products, a scrutiny of the pharmacokinetic data that compare blood levels after 
absorption is done to verify their interchangeability with the brand-name product before approval 
(1). The vulnerability of this approach to the whims and caprices of manufacturers of substandard, 
fake, counterfeit and adulterated products syndicates, who collude with local distributors to 
`push' into the distribution systems drugs of standards other than those that have been registered, 
can not be taken for granted. Documentary evidence by the BBC has linked fake drug products 
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marketed in Nigeria to syndicates in China, Egypt, India, Indonesia and Pakistan with 
collaborators in Nigeria (8) 
In 1977, US FDA bioequivalence regulations set forth some criteria for establishing 
bioequivalent requirement of a drug product including, among others (9), 
Evidence from controlled trials or observations that such products do not give 
comparable therapeutic effects. 
Evidence from well controlled bioequivalence studies that the products are not 
bioequivalent 
Evidence that the drug product exhibit a narrow therapeutic index 
Competent medical determination that a lack of bioequivalence can have serious 
adverse effects in treatment or prevention of a serious disease or condition. The 
presence of specific inactive ingredients (e.g. hydrophilic or hydrophobic excipients) 
that may be required for absorption of the active drug or may interfere with such 
absorption (10) 
Historically there have been concerns regarding the bioequivalence of multi-source drug 
products. In 1974, concerns about bioinequivalence led to the establishment of the Drug 
Bioequivalence Study Panel of the Office of Technology Assessment (OTA). The objective of 
the panel was to ensure that drug products with similar chemical composition and physical 
properties produce similar therapeutic effects. It was observed that not all chemical equivalents 
were interchangeable (10). This observation lead Koch-Weiser (1974) to conclude that 
bioinequivalence of different drug products appeared to be more common than 
Bioinequivalence has been reported for phenytoin, phenylbutazone, chloramphenicol, 
tobutamide. The clinical significance of these differences relate to the therapeutic index of the 
drug, the type of disease being treated and the dose of the drug (10) 
In 1989, the US Federal investigators uncovered several issues concerning generic industry. 
Generic drug industry officials were implicated in the conduct of fraud, obstruction of justice and 
non-compliance with various manufacturing procedures. It was also found that several FDA 
employees accepted illegal compensations in exchange for information and assistance that gave 
certain firms an advantage in the approval process. In addition, about ten generic companies had 
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submitted fraudulent data related to bioequivalency, stability testing, and manufacturing 
protocols for some of their products. 
There has been a growing concern in the scientific community about the bioavailability problems 
of drug products on the market (10) 
1.1 Responsibility of the Health Care Practitioners 
A major role and responsibility of pharmacists involves product selection among available 
brands of drug products from different manufacturers. The pharmacist ability to make decisions 
in this regard will call for knowledge of biopharmaceutics, in particular bioavailability and 
bioequivalence of products. The potential cost savings to patients may play an important role in 
this decision (11) but quality of the product should form the baseline (12) 
The more pertinent the data available, the more comfortable is the practitioner in arriving at a 
dependable decision. In uncovering the bio-inequivalence among products, one solution is to 
clinically test for efficacy. The incidence of in vivo bioinequivalence among products or different 
batches of a product has called for increased demand for quantitative data on the therapeutic 
equivalence of certain drugs (11) 
Data from the United States of America (USA) showed an increasing trend of pharmacist control 
in dispensing decision from 16% in 1983 to 41% in 1993. The selection of multi-source product 
has become a professional responsibility of pharmacists. In drug product selection, the 
pharmacist should consider therapeutic efficacy, safety and the patient specific condition. 
Therefore, the most important parameters for arriving at a decision point are patient's economy, 
reputation of the product manufacturer and product bioequivalence and conformity to official 
standards. High efficiency in this regard would imply selecting the most cost-effective product, 
thereby making the best use of the limited health care resources. Obviously, the third option 
would be most challenging to the pharmacist as it would require the application of the principles 
of biopharmaceutics and pharmacokinetics (10). Hence, it has been observed that reputation and 
quality history of the company are the most common employed criteria in product selection. 
Thus, routine post marketing surveillance of product quality and conformity to the initial 
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standards on which market authorization was based can contribute significantly to the accuracy 
of drug product selection decision making by the dispensing pharmacists. 
1.2 Applicability of in vitro Dissolution test to Product Selection 
Instead of relying solely on company reputation and quality history, in vitro dissolution testing 
could provide additional and a more realistic approach to product selection. It could provide a 
useful index of bioavailability and bioequivalence. Following oral administration, drug 
absorption from a solid dosage form depends on the release of drug substance from the product, 
the dissolution or solubilization of the drug under physiologic conditions and the permeability of 
the therapeutic agent across the biomembrane of the gastrointestinal tract (7) . Because of the 
critical nature of drug dissolution from dosage form and solubility in physiologic fluids, in vitro 
dissolution may serve a useful guide in the prediction of in vivo performance. Thus, in vitro 
dissolution test for immediate release solid oral dosage, such as tablets and capsules is being 
used to: 
Assess the lot-to-lot quality of a drug product 
guide the development of new formulations 
Ensure sustenance of product quality on continuous basis 
Ascertain maintenance of product quality and performance after modification or changes 
to formulation, manufacturing process, site of manufacture and scale up of a 
manufacturing process. 
The knowledge of solubility, permeability, dissolution and pharmacokinetics of drug products 
are considered in defining dissolution test specifications for drug approval processes and for 
ensuring product's sameness under scale-up and post approval changes. 
The in vitro dissolution specifications for generic drug products are established based on a 
dissolution profile in relation to previously documented acceptable clinical, bioavailability 
and/or bioequivalence studies. Thus, the dissolution specifications for batch-to-batch quality 
assurance published by in the USP as compendia standard is the official specification for all 
subsequent immediate release (IR) products with the same active ingredients and, hence, could 
serve as a primary standard for product comparisons and selection. 
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1. 3. Problem Statement/Research Questions 
According to the Jamaican Food and Drug Regulations (1975) Section 40 (1) (a), "A person shall 
not sell, manufacture, import or distribute a drug unless the drug has been registered with the 
Ministry of Health. Section 41 (1) states that "A person shall not manufacture a drug unless he 
has applied for and has been granted a permit to do so by the minister". In addition, section 43 
(2) (b) stipulates that, before an imported drug is released for sale, the minister may request the 
importer to conduct tests in Jamaica by an acceptable method, on that drug in the form in which 
it is sought to be imported (13). It is evident, therefore, that adequate measure is in place for the 
control of drug product quality. With the plethora of regulations and ordinances in various 
countries where incidences of fake drug, adulterated and counterfeit products have been reported, 
including the United States, is it certain that manufacturers are complying with the regulatory 
requirements for their products? Are batches of anti-hypertensive drug products being tested and 
found satisfactory before being admitted into the Island of Jamaica? Are products containing the 
same active ingredients in the same amount and in the same type of dosage form truly 
bioequivalent? Is there any justification for patients to insist on a particular brand or generic, 
refuse substitution even though Pharmacy Law in Jamaica promotes generic dispensing and 
actually mandates pharmacists to erect notices informing patients of availability of generics? 
In light of the research problem, the results of the investigation should find relevance in guiding 
pharmacists and physicians in product selection for their patients, to influence the relevant 
authority to activate the mechanism for documentation and reporting by pharmacists and 
physicians of patients' complaints and sub-clinical responses to treatments, to improve patients' 
confidence in generic products, to influence policies on generic drug selection for government 
programs, to add to the body of knowledge on brand - generic bioequivalence investigations and 
suggest, based on dissolution studies, formulation considerations. With the availability of several 
generic drug alternatives on the market, bioequivalence data will assist health care agencies, 
pharmacists and physicians to make better product selections for the patients. The resulting 
feedback from this process will alert the manufacturers to the necessity of ensuring that their 
products will not fail the built in quality of design and performance in the market place. 
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1.4. Aims and Objectives of this Study 
The primary aim of this study was to investigate the pharmacoeconomic and quality implications 
of anti-hypertensive drug product selection among brands and generic products available in 
Jamaica. It should be possible to correlate the biopharmaceutical and bioequivalence properties 
of these products with the current patient experiences when on the therapy. 
Some of the specific objectives of the study are to: 
Assess the physical quality and presentation of some random selection of 
antihypertensive drug products containing atenolol, captopril, methyldopa and nifedipine 
Assess their uniformity of weight 
Assay the tablets content of active ingredients 
Conduct dissolution tests and determine the dissolution profiles of the products 
Determine the comparative amount of API released at specified time points 
Establish the substitutability of tested brand (innovator products) with the generics using 
the similarity factors of the amount dissolved at specified time points. 
2. Methodology 
2.1. Materials 
2.2.1. Chemicals and Reagents 
The following chemicals and reagents used in the study were sourced as follows: Potassium 
phosphate monobasic , Sodium Hydroxide Pellets, Potassium Bicarbonate and Sodium 
Bicarbonate (Mallinckrodt Baker Inc., Phillipsburg, NJ); di-sodium disulphide, trisodium 
citrate, iron (II) sulphate (BDH, Poole, England); Cone. HCI, Ammonium hydroxide, cone. 
sulphuric acid and methanol (HPLC/UV grade) were products of PHARMCO, Brookfield, 
CT). All reference standards (Atenolol US CRS, Captopril US CRS, Furosemide US CRS 
and Methyldopa US CRS) were obtained from 
2.2.2. Methods 
2.2.1. Drug Products 
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Commercial products in four pharmacological class of antihypertensive were selected 
randomly, using assigned random numbers from a statistical table (Jones, 2002). Samples 
(200 tablets each) were sourced from distributors in Kingston through the UTECH 
Pharmacy. No prior knowledge of the purpose of product collection was available to the 
distributors. Detailed information on products packages were recorded including 
Manufacturers, batch numbers, date of manufacture and expiry, dose size, type of 
packaging and size of package. 
Table 1. Drug products selection protocols 
Class of Drug Brand/Generics Comment 
Diuretic F3 Innovator 
Brand 
4 generic analogues were identified, only 2 
could be sourced (F1 & F2) 
Furosemide Standard Chemical (US CRS) Reference 
Beta-Adrenoceptor Blocker Atenolol A4 Innovator 
Brand 
11 generic analogues were identified, three were 
randomly selected for study (Al, A2 and A3) 
Atenolol Standard Chemical (US CRS) Reference 
Angiotensin Converting 
Enzyme Inhibitor (ACEI) 
Captopril C3 Innovator 
Brand 
6 Generic analogues were identified, only 2 
could be sourced (Cl & C2) 
Ca to ril Standard Chemical (US CRS) Reference 
Central Alpha Blocker Methyldopa M1 Innovator 
Brand 
Only one generic analogue exists in the market 
(M2) 
Methyldopa Standard chemical (US 
PCRS) 
Reference 
2.2.2. Assignment to treatments 
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Products in the same pharmacological class were listed alphabetically. The order of 
treatment was then assigned using random numbers from a statistical table (Jones, 2002) 
2.2.3. Weight variation 
At least twenty (20) randomly selected tablets from each batch or lot were weighed on an 
Adventurer electronic balance (OHAUS, Pine Brook, NJ). The average weight and 
coefficient of variation were computed on a Microsoft Excel spread sheet. 
2.2.4. Assay of content of active ingredients 
The British Pharmacopoeia procedures were followed. The procedures are summarized 
below. 
2.2.4.1 Atenolol tablets 
Twenty atenolol (50 mg) tablets were weighed on Adventurer electronic balance (OHAUS, Pine 
Brook, NJ) and ground in a glass mortar with pestle. The powder was transferred into a 500-m1 
flask using 300 ml of methanol. The resulting suspension was heated to 60°, shaken for 15 
minutes, cooled and diluted to 500 ml with methanol. The mixture was filtered using Whatman 
Millipore 0.45 im membrane filter. Half (0.5) ml of the filtrate was diluted to 10 ml with 
methanol and the absorbance was measured at 275 nm on a Unicam S 10 Spectrophotometer (Pye 
Unicam, England). The content of C14H22N203 (Atenolol) was calculated, taking 53.7 as the 
value of A (1%, 1 cm) at the maximum at 275 nm (14) . Results represent average of three 
determinations. 
2.2.4.2. Furosemide Tablets 
Twenty Furosemide (40 mg) tablets were weighed and powdered in a glass mortar with pestles. 
A quantity of the powder containing 0.2 g of Furosemide was shaken with 300 ml of 0.1M 
sodium hydroxide.for 10 minutes. The mixture was made up to 500 ml 0.1M sodium hydroxide 
and filtered through Whatman 0.45 µm Millipore filter. Five (5) ml sample was diluted to 250 ml 
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with O.1M sodium hydroxide and the absorbance was measured at 271 nm (BP 2001) (14). The 
content of C12H 11C1N2O5S (Furosemide) was calculated taking 580 as the value of A (1%, 1 cm) 
at the maximum at 271 nm. The procedure was replicated twice. 
2.2.4.3. Methyldopa Tablets 
Twenty 500 mg tablets of methyldopa were weighed on a Adventurer electronic balance 
(OHAUS, Pine Brook, NJ). A quantity of the powder containing the equivalent of 0.1 g of 
anhydrous methyldopa was dissolved as completely as possible in sufficient 0.05M sulphuric 
acid to produce 100 ml and filtered. To 5 ml of the filtrate was added 2 ml of iron (II) sulphate- 
citrate solution, 8 ml of glycine buffer solution and sufficient water to produce 100 ml. The 
absorbance of the resulting solution was measured on a Unicam spectrophotometer at the 
maximum at 545 urn (BP 2001) (14) . The procedure was repeated using 5 ml of a 0.10% w/v 
solution of methyldopa BPCRS in place of 5 ml of the filtrate. The content of C10H13NO4 
(methyldopa) was calculated using the declared content of C10H13NO4 in methyldopa BPCRS. 
The procedure was repeated twice. 
2.2.5. Dissolution rate tests 
In each dissolution test, a randomly selected tablet was weighed on Adventurer electronic 
balance (OHAUS, Pine Brook, NJ) and placed in 900 ml of fluid specified in the product 
monograph (BPIUSP) i.e. phosphate buffer pH 5.8 (for Furosemide tablets) and 0.1 N HCl for 
Atenolol, Captopril and Methyldopa tablets, in the hemispherical vessel of the Erweka DTZ 
dissolution chamber. Test temperature was maintained at 37 ± 0.5 °C and the stirrer speed at 50 
rpm. Ten (10)-ml samples were taken at pre-determined time intervals and replaced with 10 ml 
of fresh medium maintained at the same temperature on a Thermostat hot Plate. Absorbance 
reading of solutions were taken on a Unicam Hey, IOS spectrophotometer (Pye Unicam, England) 
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at the absorption maximum specified in the BP/USP) i.e. of 275nm for Atenolol, 212 rim for 
Captopril, 274 rim for Furosemide and at 280 nm for Methyldopa. Amount of drug in solution 
was determined by converting absorbance readings to mg using the conversion factor obtained 
from a prepared calibration curves or using the value of A"'* specified in the monograph of the 
respective substance. Results represent average of several determinations 
RESULTS AND DISCUSSION 
1. Physical Characteristics of the Tablets 
The physical features of the commercial anti-hypertensive tablets are shown in table 1 below. In 
the atenolol group, Al and A4 are white while A3 is off-white and A2 is dark orange in colour. 
Scoring, film coating and markings on the tablet all serve additional benefits of 
attractiveness/elegance, protection and ease of swallowing, identification and facilitate 
administration of fractional doses. Type and size of packaging material are all important 
considerations on cost: Al comes in 100 unit packs and with an average cost per tablet of ... A2 
and A4 are calendar packs of 28 in two blister packs while A3 also comes in blister packs but 
with only 10 tablets per pack and average cost of ... per tablet. While high organoleptic qualities 
of tablets are desirable, they should not be such as to add too much to the overall cost of the 
products. Absence of these physical effects is one of the reasons why generic products are often 
cheaper than the brand. 
Table 1 Physical characteristics, packaging and cost of commercial antihypertensive drug 
products marketed in Jamaica 
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Chemical Pharmacological Brand/Generic Physical Primary # of Units/ Average 
Name Class' Code Characteristics Packaging Pack Cost/Tablet 
Material ) ($) 
Atenolol Beta Adrenoceptor Al White, flat bevel edge, Plastic 100 5.29 
(50 mg) Blocking Agent (B- scored, with Bottle; 
Blocker) markings on both faces tamper 
evident 
A2 Dark Orange, Blister pack 28 (2 x 14 4.46 
biconvex, (2) tablets) 
film coated, 
not scored 
A3 Off-white, Blister pack 10 - 
convex/concave faces, (1) 
film coated, 
scored with 
marking on one face 
A4 White, uncoated, Blister pack 28 (2 x 14 7.32 
biconvex with marking (2) tablets) 
on one face, not scored 
Captopril Angiotensine Cl White, uncoated, Plastic 100 9.37 
(25 mg) Converting Enzyme rectangular double- bottle, 
Inhibitor scored tablets with tamper 
markings on one face evident 
only 
C2 White concave/convex Blister pack 10 - 
round tablet, double- 
scored on one face 
only 
C3 White, flat with bevel 30 (3 x10) 21.43 
edge, double-scored on tablets 
one face only 
Furosemide Diuretic F1 Yellow, flat face with Plastic 500 1.58 
bevel edge, scored and bottle, 
markings on one face tamper 
only evident 
sealing 
F2 White, flat face with Blister pack 28 (2 x14) 6.02 
bevel edge, scored and tablets, 
markings on one face calendar 
only pack 
F3 White, flat face with Blister pack 10 x 25 13.06 
bevel edge, markings in cardboard blisters 
on both faces, scored box 
on one face only 
Methyldopa Central Alpha Ml Dark yellow, biconvex, Blister pack 30 (3 x 10 11.30 
Blocker (a- film coated tablets, (3) tablets) 
Blocker) marking on one face 
only 
M2 Cream, biconvex, film 6.12 
coated, no markings 
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1. Tablet weight variation 
Average weight of tablets and the standard deviations are shown in Table 2 below. In the 
Atenolol group, the order of increasing weight variation is A2 < A4 < Al < A3. Thus, 
Atenolol group A3 has the poorest consistency in tablet weight while group A2 has the 
highest consistency. Tablet weight variation influences the content of active ingredient 
variation and as such, a limit has been set in the BP. Deviation of individual tablet weight 
from the average group weight is shown in Table 3 below. Values of the range are shown in 
Table 3. However, all group of products passed the BP limit test for weight variation. Since 
different manufacturers have their specific % of basic formulation which comprised of active 
drug, the absolute weights can not be compared. However, weight variation, which assesses 
the consistency of unit dosage, is a good parameter for comparative evaluation of the 
respective products. According to the British Pharmacopoeia (2001)(14), for uncoated and 
film coated tablets weighing 80 mg or less, no individual tablet weight should deviate from 
average weight by more than 10 %, while for tablets weighing more than 80 mg but less than 
250 mg, deviation should not be more than 7.5 %. Captopril group C3 has the best 
consistency in tablet weight uniformity (Appendix 5) with range of ± 1.22, followed by Cl 
(±2.03 % deviation) and C2 with a deviation of ± 4.88 % respectively. BP requires a 
deviation of < 10% for captopril tablet size. In the Furosemide group, rank order of weight 
uniformity was F2 < F3 < F 1, with deviations of ± 0.72 %, ± 1.44 % and 5.05 % respectively. 
Methyldopa M1 was more consistent than M2 with deviations of ± 1.03 % and 1.67 % 
respectively. BP requires a deviation of less than 5 % for methyldopa tablets. On the basis of 
weight uniformity, which ascertains the ability of the tablet to retain tablet constituents from 
manufacturer to the patient, products within each pharmacologic class can be interchanged. 
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Table 2 Tablet weight variation (mg) 
Brand/Generic 









Group 1 120.57± 2.64 95.52 ± 1.04 161.56 ± 0.53 711.09 ± 4.38 
Group 2 225.86 ± 1.33 101.97 ± 1.66 158.32 ± 4.01 714.86 ± 6.01 
Group 3 214.19± 3.42 140.60 ± 0.70 159.56 ± 1.27 - 
Group 4 212.69 ± 2.51 - - - 
*Brand product is highlighted in bold. 
Table 3 Percent Deviations in tablets weights of commercial antihypertensive drug 
products 
Brand/Generic 
(A,C,F & M) 
Range of weight deviations 
Atenolol (mg %) 
Official limit: < 10 % 
Captopril (mg %) 
Official limit: < 10 % 
Furosemide (mg %) 
Official limit: < 10 % 
Methyldopa (mg %) 
Official limit: < 5 % 
Group 1 -7.65 - +3.85 -1.94 - +2.04 -0.72 - +0.46 -1.88 - +1.59 
Group 2 -1.46 - +1.16 -1.66 - +4.88 -5.05 - + 4.69 -1.67 - + 1.98 
Group 3 -3.57 - + 3.35 -1.22 - +0.78 -1.05 - + 1.45 
Group 4 -3.30 -+ 2.21 - - 
*Brand product is highlighted in bold. 
3. Assay of drug content 
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The per cent content of active ingredients among the four different group of antihypertensive 
drug products are shown in Table 4. The rank ordering of the content of active ingredients are 
atenolol group A3 > A4 > A2 > Al (p > 0.05); Furosemide group F3 > F 1 (p > 0.05), F2 > F3 (p 
> 0.05), F2 > F3 (p < 0.05). Thus, the difference in drug content of F2 and F3 is significant and 
they may not be substituted one for the other. Drug content of methyldopa tablets are not 
significantly different and they may be interchanged one with the other on the assurance of 
equivalent amount of drug content. 
Table 4 Assay of Drug Content 
Brand/Generic Atenolol 
%LC 












(BP Limit: 95 - 105 
%)** 
Group 1 96.03 ± 0.47 - 97.56 ± 0.50 115.17 ± 2.03 
Group2 96.40±1.68 - 95.11±1.53 113.73±1.18 
Group 3 99.32 ± 1.13 
- 
- 95.76 ± 2.16 - 
Group 4 98.08 1 T8?- - I- - 
LC is the percent of label content **British Pharmacopoeia (2001). The two methyldopa % 
products were outside the upper limit 
Table 5 Pair wise comparison of % of label content of different atenolol tablet products 
marketed in Jamaica 
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Sig. (2- 
Paired Differences t df tailed) 
Std. 95% Confidence 
Std. Error Interval of the 
Mean Deviation Mean Difference 
Lower Upper 
Pair Atenolol Al 
1 (% label 
content) - - 3.73834 2.15833 7 61056 - 777 2 .519 




Pair Atenolol A2 
2 (% label 
content) - - 
Atenolol A4 2.04842 
2.37750 1.37265 -7.95444 3.85761 -1.492 2 .274 
(% label 
content) 
Pair Atenolol A3 
3 (% label 
content) - 
Atenolol A4 
1.24147 2.79537 1.61390 -5.70261 8.18554 .769 2 .522 
(% label 
content) 
Pair Atenolol Al 
4 (% label 
content) - - 
Atenolol A3 2.91744 
5.60003 3.23318 
16.82868 
10.99379 -.902 2 .462 
(% label 
content) 
Pair Atenolol A2 
5 (% label 
content) - - 3.12901 1 80653 4 48301 821 -1 2 210 
Atenolol A3 3.28988 
. 
11.06277 
. . . 
(% label 
content) 
Pair Atenolol Al 
6 (% label 
content) - 
Atenolol A2 




Table 6 Pair wise comparison of % of label content of different Furosemide tablet products 
marketed in Jamaica 
Paired Differences 
95% Confidence 
Interval of the 
Std . 
Difference 
Std E Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair Furosemide F1 
1 % label 
content - -.64655 3.67641 2.12258 -9 779 48616 8 - 305 2 .789 
Furosemide F3 
. . . 
% label 
content 
Pair Furosemide F2 
2 % label 
content - 
1.79596 2.51639 1.45284 -4 455 8 04703 236 1 2 .342 
Furosemide F3 
. . . 
% label 
content 
Pair Furosemide F 1 
3 % label 
content - - 1.18696 .68529 -5.391 50608 2 .070** 





**Statistically significant difference 
Table 7 Pair wise comparison of % of label content of different Methyldopa tablet products 




Interval of the 
Std. 
Difference 
Std E Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair Methyldopa 
1 MI % label 
content - 
1.44256 2.77371 .98065 3.76144 1.471 7 .185 
Methyldopa .87632 
M2 % label 
content 
4. Rate of Drug Dissolution from Tablets 
Results of Beer-Lambert (calibration) curves for standard atenolol, captopril, furosemide and 
methyldopa US Chemical Reference Substances (US CRS) are shown in Figs. 1, 3, 5 and 7 
respectively. An almost perfect linearity was obtained in the regression of absorbance values on 
concentrations of drugs in solution. This high degree of linearity is confirmed by the variance of 
the equations. The variances (R) for atenolol, captopril, furosemide and methyldopa were 
0.9963, 0.9854, 0.9950 and 0.9999 respectively. This indicates that the equations of the 
respective line can be used to convert absorbance values to concentrations in the relevant range. 
The dissolution profiles of atenolol tablets are shown- in Fig. 2. Atenolol Al and A3 started 
dissolving earlier (at 5 min.) than the brand (A4)(p = 0.000) while A2 was slower dissolving 
(Table 9). By 10 minutes, the brand was significantly higher in amount dissolved relative to the 
generic A2 (p = 0.003). The maximum amount of drug released (Qpeak) was significantly higher 
with brand (A4) than with the generic A2 (p = 0.005) while values were comparable among other 
generics and the brand (p > 0.05). In addition, time for maximum drug release (Tpeak) was 
significantly longer with generic A2 than with brand (p = 0.006) whereas it was significantly 
shorter with generic Al. The results suggest that generic A2 requires caution in its substitution 
for the brand (A4). Al and A3 can be interchanged and or substituted for the brand without fear 
of delay in patient time to benefit from the drug action. 
21 
Among the captopril group, dissolution profiles were generally comparable. However, drug 
dissolution started earlier with the brand (A3) than the two generics and the difference was 
statistically significant for generic C2 (p = 0.000). By the 10 and 15 minute sample points, the 
dissolution rates were comparable (p > 0.05) (Tables 14 & 15). Although Qpeak appeared to be 
significantly higher from C2, Tpeak was also significantly longer than with the brand (C3). 
Generally, it appears that the generic captopril can be substituted for the brand without any delay 
in patient therapeutic experience. 
The generic Furosemide F1 and F2 showed higher dissolution at 5 and 10 minutes sample points 
than the brand and the difference between F2 and F3 was significant at 10 min (P= 0.057 and 
0.002 respectively at 5 and 10 minutes). By 30 minutes, however, dissolution rates were 
comparable (p >0.05). The peak amounts and the time to peak were comparable (p > 0.05). 
With the methyldopa products, the brand started dissolving earlier (p = 0.000, at 5 min.)(Table 
24), but the eventual dissolution profiles were comparable (p > 0.05 at 10 min.) (Table 25). 
Although the maximum amounts of drug released were comparable, the time for peak release 
was significantly shorter for brand than for generic. Thus, patient may experience faster response 
to brand than to generic methyldopa. 
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Fig. 1. Absorbance-concentration curve for 












0 0.005 0.01 
Conc. (% wlv) 
0.015 
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Fig. 2. Dissolution profiles of 








20 40 60 80 
Time (Min.) . Al --w- A2 A3 A4 
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Table 9 Atenolol generic versus brand comparisons of amount dissolved in 5 minutes 
Sig. (2- 
Paired Differences t df tailed) 
95% 
Std. Confidence 
Std. Error Interval of the 




Al (5 MIN) 
15.0667 8.46864 2.44468 9.686 20.4474 6.163 11 .000** 
ATENOLOL 






-1.1600 10.82501 3.12491 -8.037 5.7179 -.371 11 .718 
ATENOLOL 
A4 (5 MIN) 
Pair 
3 ATENOLOL 
A3 (5 MIN) 
5.7542 12.20553 3.52343 -2.001 13.5092 1.633 11 .131 
ATENOLOL 
A4 (5 MIN) 
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Interval of the 
Std . 
Difference 
Std E Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair ATENOLOL 
1 Al (5 MIN) - 15.0667 8.46864 2 44468 9.686 4474 20 6.163 11 .000** ATENOLOL . . 
A4 (5 MIN) 
Pair ATENOLOL 
2 A2 (5 MIN) 
ATENOLOL 
-1.1600 10.82501 3.12491 -8.038 5.7179 -.371 11 .718 
A4 (5 MIN) 
Pair ATENOLOL 
3 A3 (5 MIN) - 
5.7542 12.20553 52343 3 -2.001 5092 13 1 633 11 .131 ATENOLOL . . . 
A4 (5 MIN) 
Table 11 Atenolol generic versus brand comparisons of amount dissolved in 10 minutes 
Sig. (2- 
Paired Differences t df tailed) 
95% 
Std. Confidence 
Std. Error Interval of the 
Mean Deviation Mean Difference 
Lower Upper 
Pair ATENOLOL 
1 Al (10 MIN) - 1.4583 3.14376 90752 -.5391 4558 3 1.607 11 .136 
ATENOLOL 
. . 
A4 (10 MIN) 
Pair ATENOLOL 
2 A2 (10 MIN) - - 5 71372 64941 1 -9 780 -2 519 -3.728 11 .003** 
ATENOLOL 6.1492 
. . . . 
A4 (10 MIN) 
Pair ATENOLOL 
3 A3 (10 MIN) - 










Interval of the 
Std. 
Difference 
Std E Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair ATENOLOL 
1 Al Qpeak - 
_ 7275 3.63185 1.04843 -3.035 1.5801 -.694 11 .502 ATENOLOL 
A4 Q peak 
Pair ATENOLOL 
2 A2 Qpeak - -3.209 3 20109 92407 -5 243 -1.175 -3.473 11 .005** ATENOLOL 
. . . 
A4 Q peak 
Pair ATENOLOL 
3 A3 Qpeak - 
ATENOLOL 




Table 13 Atenolol generic versus brand comparisons of time required for release of 
maximum amount of drug (Tpeak) 
Paired Differences 
95% Confidence 
Interval of the 
Std. 
Difference 
Std E Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair ATENOLOL 
1 Al Tpeak - 9.57585 2.76431 -8.2491 11 .000** 
ATENOLOL 14.3333 20.4175 5.185 
A4 Teak 
Pair ATENOLOL 
2 A2 Tpeak - 13.3333 13.70689 3.95684 6244 4 22 0423 3.370 11 .006** ATENOLOL . 
. 
A4 T peak 
Pair ATENOLOL 
3 A3 Tpeak - 
7 5000 19 59824 5.65752 -4 9521 19 9521 326 1 11 .212 ATENOLOL 
. . . . . 
A4 T peak 
**Statistically significant 
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Fig. 3 Calibration curve for Captopril US CRS 
0.3 
0 
0 0.0002 0.0004 0.0006 0.0008 0.001 0.0012 
Conc. (% w/v) 
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Fig. 4. Dissolution Profiles of some 
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Table 14 Comparisons of amount of captopril dissolved in 5 minutes from brand and 
generic tablets 
Sig. (2- 
Paired Differences t df tailed) 
Std. 95% Confidence 
Std. Error Interval of the 
Mean Deviation Mean Difference 
Lower Upper 
Pair CAPTOPRIL 
1 C1 5 MIN 
DISSOL - -1.0750 9.37295 4.68647 -15.99 13.8395 -.229 3 .833 
CAPTOPRIL 
C3 5 MIN 
DISSOL 
Pair CAPTOPRIL 
2 C2 5 MIN 
DISSOL - - 5.82658 2.91329 -60.14 -41.599 -17.46 3 .000** CAPTOPRIL 50.8700 
C35MIN 
DISSOL 











Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair CAPTOPRIL 
1 C1 10 MIN 




2 C2 10 MIN - .4950 5.78523 2.89261 -8.711 9.7006 171 3 875 CAPTOPRIL . . 
C3 10 MIN 
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Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair CAPTOPRIL 
1 Cl 15 MIN 
DISSOL - .6600 5.03469 51734 2 -7 351 6713 8 262 3 .810 CAPTOPRIL 
. . . . 
C3 15 MIN 
DISSOL 
Pair CAPTOPRIL 
2 C2 15 MIN 
DISSOL - 
CAPTOPRIL 
3.3675 3.83299 1.91650 -2.732 9.4666 1.757 3 .177 
C3 15 MIN 
DISSOL 









Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair CAPTOPRIL 
1 C1 Qpeak - 
CAPTOPRIL 
-.1025 5.24315 2.62158 -8.446 8.2405 -.039 3 .971 
C3 Q peak 
Pair CAPTOPRIL 
2 C2 Qpeak - 




Table 18 Comparison of time for maximum amount of captopril dissolved (Tpeak) from 
brand and generic tablets 
Paired Differences 
95% Confidence 




Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair CAPTOPRIL 
1 C1 Tpeak - 
3.0000 4 76095 2 38048 -4 576 10 5757 1.260 3 .297 
CAPTOPRIL 
. . . . 
C3 T peak 
Pair CAPTOPRIL 
2 C2 Tpeak - 
13.0000 2.44949 1.22474 9.1023 16.8977 10.614 3 .002** CAPTOPRIL 
C3 T peak 
**Highly statistically significant 
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Fig.5. Calibration curve for 
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Fig. 6 Dissolution Profiles of Commercial 
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Table 19 Comparisons of amount of Furosemide dissolved in 5 minutes from brand and 
generic tablets 
Sig. (2- 
Paired Differences t df tailed) 
Std. Std. 95% Confidence 
Deviatio Error Interval of the 
Mean n Mean Difference 
Lower Upper 
Pair FUROSEMIDE 
1 F1 5 MIN 
F 18.4675 27.57435 78718 13 -25 409 344 62 1.39 3 .273 UROSEMIDE . . . 





21.8150 14.50515 7.25258 -1.2659 44.896 3.00 3 .057* 
F UROSEMIDE 
F3 5 MIN 
DISSOL 
Pair FUROSEMIDE 
3 F1 5 MIN 
DISSOL - -3 3475 29.11717 14 55858 -49 679 984 42 - 230 3 .833 
FUROSEMIDE 
. . . . . 
F2 5 MIN 
DISSOL 
*Statistically significant difference 
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Interval of the 
Std. Sig. 
Difference 
S d E 2 t . rror ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair FUROSEMIDE 
1 F1 15 MIN 
DISSOL - 8,9700 25.66992 12.83496 -31.876 49.8166 .699 3 535 
FUROSEMIDE 
. 
F3 15 MIN 
DISSOL 
Pair FUROSEMIDE 
2 F2 15 MIN 
DISSOL - 
FUROSEMIDE 




3 F1 15 MIN 
DISSOL - - 
FUROSEMIDE 12.1150 
25.52321 12.76160 -52.728 28.4981 -.949 3 .412 
F2 15 MIN 
DISSOL 
**Highly statistically significant difference 
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Table 21 Comparisons of amount of Furosemide dissolved in 30 minutes from brand and 
generic tablets 
Sig. (2- 
Paired Differences t df, tailed) 
Std. 95% Confidence 
Std. Error Interval of the 
Mean Deviation Mean Difference 









2 F2 30 MIN 
DISSOL - 
FUROSEMIDE 
7.9700 7.70539 3.8527 -4.2910 20.231 2.069 3 .130 




DISSOL - -11.705 13.75717 8786 6 -33.596 10.186 -1.702 3 .187 
FUROSEMIDE 
. 
F2 30 M1N 
DISSOL 
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Table 22 Comparison of maximum amount of Furosemide dissolved (Qpeak) from brand 
and generic tablets 
Paired Differences 
95% Confidence 






Si 2 . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair FUROSEMIDE 
1 F1 Qpeak - 
FUROSEMIDE 
3.0525 7.07821 3.53910 -8.211 14.3155 .863 3 .452 
F3 Qpeak 
Pair FUROSEMIDE 
2 F2 Qpeak - 
7,6975 7.34981 3.67490 -3.998 19.3927 2.095 3 .127 
FUROSEMIDE 
F3 Q peak 
Pair FUROSEMIDE 




Table 23 Comparison of time for maximum amount of Furosemide dissolution (Tpeak) 
from brand and generic tablets 
Sig. 
(2- 
Paired Differences t df tailed) 
Std. Std. 95% Confidence 
Deviatio Error Interval of the 
Mean n Mean Difference 
Lower Upper 
Pair FUROSEMIDE 
1 F1 Tpeak - 
FUROSEMIDE 
12.500 28.72281 14.36141 -33.204 58.2044 .870 3 .448 
F3 T peak 
Pair FUROSEMIDE 
2 F2 Tpeak - -7,5000 9.57427 4.78714 -22.735 7348 7 -1.57 3 215 
FUROSEMIDE 
. . 
F3 T peak 
Pair FUROSEMIDE 
3 F1 Tpeak - 




Fig. 7 Calibration curve for 
methyldopa LISP CRS 
Concentration (% w/v) 
0 0.002 0.004 0.006 0.008 
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Std E 2 . rror ( - 
Mean Deviation Mean Lower Upper T df tailed) 
Pair METHYLDOPA 
1 Ml (5 min.) - 22,5175 5.19444 1.49951 19.2171 25.8179 15.017 11 .000** 
METHYLDOPA 
M2 (5min) 





Std. Interval of the 
Std Error Difference Si (2- . g. 
Mean Deviation Mean Lower U per t df tailed) 
Pair METHYLDOPA 
1 M1 (10 min.) - 3.0042 10.72788 3.09687 9.8203 .970 11 .353 
METHYLDOPA 3.8120 
M2 (10 min.) 
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Table 26 Comparison of maximum amount of Methyldopa dissolved (Qpeak) from brand 




Interval of the 
Std. 
S d E 
Difference 
Si 2 t . rror g. ( - 
Mean Deviation Mean Lower Upper t df tailed) 
Pair METHYLDOPA 
1 Ml Qpeak - ,8442 4 20636 21427 1 -1 828 3.5168 .695 11 .501 
METHYLDOPA 
. . . 
M2 Q peak 
Table 27 Comparison of time for maximum amount of Methyldopa dissolution (Tpeak) 
from brand and generic tablets 
Sig. (2- 
Paired Differences t df tailed) 
95% 
Std. Confidence 
Std. Error Interval of the 
Mean Deviation Mean Difference 
Lower Upper 
Pair METHYLDOPA 
1 MI Tpeak 





Drug products containing nominally equal amount of active drug substances and present in 
the same type of dosage form should make the substance available for absorption as soon as 
possible after administration. Results of this study have shown that antihypertensive drug 
products in four different pharmacologic classes contain very similar levels of the active drug 
substances. They generally contain prescribed levels as specified in the British 
Pharmacopoeia (BP) 2001. An important exception is the methyldopa group which contain 
slightly higher levels of drug than is recommended in the BP. However, the two products 
marketed in Jamaica showed comparable levels of active ingredient. Hence, the tested 
generics can be fairly substituted for the brand and selected with other considerations of cost, 
availability and accessibility, elegance and patient personal preferences with the assurance of 
equivalent amount of drug substance in each brand/generic. 
Using the dissolution profiles, however, some differences were noticed on the rate and extent 
at which some generic/brand make the drug available for absorption. Atenolol brand (A4) 
showed faster rate and higher peak amount than one of the generics (A2). While Al and A3 
can be substituted for A4 with assurance of similar patient experience, this may be difficult to 
guarantee with the generic A2. 
Captopril and furosemide product categories are generally comparable and can be 
interchanged without any hindrance to drug absorption. However, with the methyldopa 
group, the shorter time for maximum drug release may make patients show response to 
therapy faster than with the generic. 
Results have shown that, generally, more than cost consideration and company reputation is 
required for day-to-day rational decision making in drug products sourcing. 
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6. Recommendations 
Routine analysis of drug products that are being distributed in the market would provide 
additional guidance on drug product selection decision making by health care professionals, 
care providers and sponsors. Sole reliance on company reputation would leave the 
distribution channel vulnerable to possible assault from substandard, fake, counterfeit and 
adulterated products. Although this assault does not seem to happen frequently, if and when 
it eventually happens, the effect is usually "one too many". In order to proactively forestall 
any possibility of "worm" in the distribution channel, routine analysis of drug content and in 
vitro dissolution testing should be instituted. Just as it assures the manufacturers of the 
quality of their product within the factory, it can also assure the public of the quality of what 
they are taking from the market. 
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APPENDICES 
Appendix 3 SAMPLE RANDOMIZATION SCHEME FOR ASSIGNMENT OF 
PRODUCT/SAMPLE TO TREATMENTS 


















































APPENDIX 4 UNIFROMITY OF WEIGHT OF ATENOLOL TABLETS 
Al A2 A3 A 4 
Weight %DEV Weight % DEV Weight %DEV Weight % DEV 
0.1208 0.192881 0.2258 -0.02657 0.2095 -2.23723 0.2117 -0.46859 
0.12 -0.4725 0.2227 -1.41895 0.2162 0.931082 0.2129 0.097698 
0.1186 -1.65852 0.226 0.061947 0.2196 2.464936 0.2131 0.191459 
0.1224 1.497549 0.2273 0.633524 0.2169 1.250807 0.2134 0.331771 
0.1237 2.532741 0.2274 0.677221 0.2193 2.331509 0.2175 2.210575 
0.119 -1.31681 0.2261 0.106148 0.2101 -1.94526 0.2147 0.935259 
0.1126 -7.07549 0.224 -0.83036 0.21 -1.99381 0.2114 -0.61116 
0.1198 -0.64023 0.2254 -0.20408 0.2144 0.099347 0.2111 -0.75414 
0.1197 -0.72431 0.2282 1.025416 0.2139 -0.13417 0.2131 0.191459 
0.1191 -1.23174 0.2247 -0.51624 0.2181 1.794131 0.2067 -2.89889 
0.1177 -2.43585 0.2251 -0.33763 0.2086 -2.67833 0.2138 0.518241 
0.1189 -1.40202 0.2267 0.370534 0.2148 0.285382 0.2153 1.211333 
0.1216 0.849507 0.2257 -0.07089 0.213 -0.55728 0.2108 -0.89753 
48 
0.1153 -4.56808 0.2253 -0.24856 0.2102 -1.89676 0.2102 -1.18554 
0.1218 1.012315 0.2241 -0.78536 0.2147 0.238938 0.2104 -1.08935 
0.1206 0.027363 0.2242 -0.74041 0.2146 0.192451 0.2099 -1.33016 
0.1174 -2.69761 0.2248 -0.47153 0.2206 2.907072 0.2133 0.285045 
0.1208 0.192881 0.226 0.061947 0.2171 1.341778 0.2079 -2.30495 
0.1206 0.027363 0.2251 -0.33763 0.2164 1.022643 0.213 0.144601 
0.1227 1.738386 0.2231 -1.23711 0.2086 -2.67833 0.2151 1.119479 
0.1185 -1.7443 0.226 0.061947 0.2125 -0.79388 0.2111 -0.75414 
0.112 -7.64911 0.2254 -0.20408 0.2104 -1.7999 0.2156 1.348794 
0.1213 0.604287 0.2255 -0.15965 0.2096 -2.18845 0.2117 -0.46859 
0.1254 3.854067 0.2255 -0.15965 0.2068 -3.57205 0.212 -0.32642 
0.1205 -0.0556 0.2249 -0.42686 0.2173 1.432582 0.2133 0.285045 
0.1213 0.604287 0.2257 -0.07089 0.2105 -1.75154 0.2147 0.935259 
0.1184 -1.83024 0.2259 0.017707 0.2142 0.006069 0.2127 0.003761 
0.119 -1.31681 0.2275 0.720879 0.2207 2.951065 0.2123 -0.18464 
0.118 -2.17542 0.2266 0.326567 0.2128 -0.65179 0.2119 -0.37376 
0.1206 0.027363 0.2271 0.546015 0.2147 0.238938 0.2136 0.425094 
0.1236 2.453883 0.226 0.061947 0.211 -1.51043 0.2149 1.027455 
0.12 -0.4725 0.2238 -0.92046 0.2089 -2.53088 0.2122 -0.23186 
0.1213 0.604287 0.2255 -0.15965 0.2132 -0.46295 0.2143 0.75035 
0.1218 1.012315 0.227 0.502203 0.2102 -1.89676 0.2083 -2.1085 
0.1202 -0.30532 0.2257 -0.07089 0.2139 -0.13417 0.216 1.531481 
0.1235 2.374899 0.2269 0.458352 0.2148 0.285382 0.2059 -3.29869 
0.1195 -0.89289 0.2282 1.025416 0.2188 2.108318 0.2133 0.285045 
0.1239 2.690073 0.2226 -1.46451 0.2132 -0.46295 0.217 1.985253 
0.1223 1.417007 0.226 0.061947 0.2132 -0.46295 0.2163 1.668054 
0.1193 -1.06203 0.2263 0.194432 0.2137 -0.22789 0.2079 -2.30495 
0.122 1.17459 0.2282 1.025416 0.2119 -1.07928 0.2107 -0.94542 
0.1191 -1.23174 0.2246 -0.561 0.2201 2.686506 0.2124 -0.13748 
0.1202 -0.30532 0.2259 0.017707 0.2123 -0.88884 0.2118 -0.42115 
0.1214 0.686161 0.2259 0.017707 0.2163 0.976884 0.2149 1.027455 
0.1234 2.295786 0.226 0.061947 0.213 -0.55728 0.2087 -1.91279 
0.12 -0.4725 0.225 -0.38222 0.2122 -0.93638 0.2107 -0.94542 
0.1236 2.453883 0.2267 0.370534 0.2216 3.345217 0.2104 -1.08935 
0.1191 -1.23174 0.2242 -0.74041 0.2173 1.432582 0.2133 0.285045 
0.1211 0.440132 0.2276 0.764499 0.2126 -0.74647 0.2132 0.238274 
0.1188 -1.48737 0.2264 0.238516 0.2151 0.424454 0.2174 2.165593 
0.1251 3.623501 0.225 -0.38222 0.2125 -0.79388 0.2145 0.84289 
0.124 2.768548 0.2273 0.633524 0.2176 1.568474 0.2107 -0.94542 
0.1193 -1.06203 0.2278 0.851624 0.2131 -0.51009 0.2132 0.238274 
0.1252 3.700479 0.2274 0.677221 0.2139 -0.13417 0.2139 0.56475 
0.1238 2.61147 0.226 0.061947 0.2195 2.420501 0.2154 1.257196 
0.1206 0.027363 0.2257 -0.07089 0.2147 0.238938 0.2136 0.425094 
0.1172 -2.87287 0.2266 0.326567 0.2133 -0.41585 0.2138 0.518241 
0.1213 0.604287 0.2247 -0.51624 0.2149 0.331782 0.2129 0.097698 
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0.1226 1.658238 0.2285 1.155361 0.2151 0.424454 0.2142 0.704015 
0.1227 1.738386 0.2263 0.194432 0.2172 1.387201 0.2155 1.303016 
0.120567 0.22586 0.214187 0.212692 
0.002637 0.001326 0.00342 0.002514 
APPENDIX 5 WEIGHT UNIFORMITY OF WEIGHT OF CAPTOPRIL ABLETS 
Cl %DEV C2 %DEV C3 % DEV 
1 0.0975 2.035897 0.1046 2.51912 0.1409 0.216466 
2 0.0951 -0.43638 0.1005 -1.45771 0.1402 -0.28174 
3 .0.0947 -0.86061 0.10,11 -0.85559 0.1407 0.074627 
4 0.0959 0.40146 0.101 -0.95545 0.1413 0.498938 
5 0.0949 -0.64805 0.1029 0.908649 0.1399 -0.49678 
6 0.0962 0.712058 0.1016 -0.35925 0.1389 -1.2203 
7 0.0967 1.22544 0.1005 -1.45771 0.1416 0.709746 
8 0.0945 -1.07407 0.1018 -0.16208 0.1403 -0.21026 
9 0.0948 -0.75422 0.1011 -0.85559 0.14 -0.425 
10 0.0952 -0.33088 0.1014 -0.5572 0.1399 -0.49678 
11 0.0949 -0.64805 0.1003 -1.66002 0.1409 0.216466 
12 0.097 1.530928 0.1018 -0.16208 0.1409 0.216466 
13 0.0968 1.327479 0.101 -0.95545 0.1409 0.216466 
14 0.0958 0.297495 0.1008 -1.15575 0.1399 -0.49678 
15 0.0946 -0.96723 0.1035 1.483092 0.1417 0.779817 
16 0.097 1.530928 0.1072 4.883396 0.1401 -0.35332 
17 0.0937 -1.93703 0.1021 0.132223 0.1414 0.569307 
18 0.0952 -0.33088 0.1022 0.229941 0.1412 0.42847 
19 0.0948 -0.75422 0.1009 -1.0555 0.1406 0.003556 
20 0.095 -0.54211 0.103 1.004854 0.1406 0.003556 
SUM 1.9103 2.0393. 2.8119 
AVE 0.095515 0.101965 0.140595 
STDEV 0.001035 0.001657 0.000699 
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APPENDIX 6WEIGHT UNIFORMITY OF FUROSEMIDE TABLETS 
F3 F l F 2 
Weight (g) %dev Weight (g) % dev Weight (g) % dev 
0.16 0.275 0.1567 -1.03063 0.1614 -0.09603 
0.1579 -1.0513 0.1624 2.515394 0.1619 0.213095 
0.158 -0.98734 0.1535 -3.13681 0.1619 0.213095 
0.16 0.275 0.1587 0.242596 0.1618 0.151422 
0.1582 -0.85967 0.1576 -0.45368 0.161 -0.34472 
0.1619 1.445337 0.1611 1.72874 0.1612 -0.22022 
0.1611 0.955928 0.1583 -0.00948 0.1611 -0.28243 
0.1592 -0.22613 0.157 -0.83758 0.1616 0.027847 
0.1587 -0.5419 0.16 1.053125 0.1617 0.089672 
0.158 -0.98734 0.1584 0.053662 0.1617 0.089672 
0.1599 0.212633 0.1645 3.759878 0.1616 0.027847 
0.158 -0.98734 0.1609 1.606588 0.162 0.274691 
0.1599 0.212633 0.1578 -0.32636 0.1604 -0.72007 
0.1598 0.150188 0.1566 -1.09515 0.162 0.274691 
0.161 0.89441 0.1541 -2.73524 0.1623 0.459026 
0.1597 0.087664 0.1507 -5.05309 0.1621 0.336212 
0.1606 0.647572 0.1635 3.171254 0.1613 -0.15809 
0.1618 1.384425 0.1557 -1.67951 0.1606 -0.59465 
0.1589 -0.41536 0.1527 -3.67714 0.1612 -0.22022 
SUM 0.1586 -0.6053 0.1661 4.686936 0.1623 0.459026 
AVE 0.15956 1.445337 0.158315 4.686936 0.161555 0.459026 
STDEV 0.001274197 -1.0513 0.004008 -5.05309 0.000526 -0.72007 
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APPENDIX 7 WEIGHT UNIFORMITY OF WEIGHT OF CAPTOPRIL ABLETS 
M1 M2 
S/N %dev % dev 
1 0.7074 -0.52205259 0.7163 0.201312299 
2 0.7105 -0.08346235 0.7186 0.520734762 
3 0.7097 -0.19628012 0.7162 0.187377827 
4 0.705 -0.86425532 0.7132 -0.23247336 
5 0.7136 0.35131726 0.7114 -0.486083778 
6 0.7099 -0.16805184 0.7217 0.948039352 
7 0.7049 -0.87856434 0.7253 1.439680132 
8 0.7112 0.01504499 0.7147 -0.022107178 
9 0.7116 0.07124789 0.7179 0.423735896 
10 0.7104 -0.09755068 0.7124 -0.345030882 
11 0.7107 -0.05529759 0.7238 1.23542415 
12 0.7094 -0.23865238 0.7069 -1.125760362 
13 0.7153 0.58814483 0.7074 -1.054283291 
14 0.7094 -0.23865238 0.7152 0.047818792 
15 0.7161 0.69920402 0.7156 0.103689212 
16 0.7084 -0.38015246 0.7098 -0.712595097 
17 0.7105 -0.08346235 0.7156 0.103689212 
18 0.7116 0.07124789 0.7177 0.395987181 
19 0.705 -0.86425532 0.7211 0.865621966 
20 0.7057 -0.76420575 0.7157 0.117647059 
21 0.7154 0.60204082 0.7093 -0.783589454 
22 0.7133 0.30940698 0.716 0.159497207 
23 0.7118 0.09932565 0.7221 1.002908184 
24 0.7103 -0.11164297 0.7031 -1.672308349 
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25 0.7144 0.46290594 0.7136 -0.176289238 
26 0.7114 0.04315434 0.7194 0.631359466 
27 0.7099 -0.16805184 0.7246 1.344465912 
28 0.7039 -1.02187811 0.7154 0.075761812 
29 0.708 -0.43686441 0.7189 0.562247879 
30 0.714 0.40714286 0.7092 -0.797800338 
31 0.7054 -0.80705982 0.7179 0.423735896 
32 0.712 0.12738764 0.715 0.01986014 
33 0.7103 -0.11164297 0.7124 -0.345030882 
34 0.7157 0.64370546 0.7125 -0.330947368 
35 0.7185 1.0308977 0.7171 0.312648166 
36 0.7072 -0.55048077 0.722 0.989196676 
37 0.7122 0.15543387 0.7161 0.173439464 
38 0.7105 -0.08346235 0.7154 0.075761812 
39 0.7148 0.5186066 0.7213 0.893109663 
40 0.709 -0.29520451 0.7228 1.098782512 
41 0.7114 0.04315434 0.7188 0.548414023 
42 0.7096 -0.21040023 0.72 0.714166667 
43 0.7171 0.83767954 0.7175 0.368222997 
44 0.7166 0.76849009 0.7199 0.700375052 
45 0.7034 -1.0936878 0.7189 0.562247879 
46 0.7132 0.29542905 0.7172 0.326547685 
47 0.7137 0.36527953 0.7293 1.980255039 
48 0.7226 1.59244395 0.7143 -0.078118438 
49 0.7203 1.27821741 0.7061 -1.24033423 
50 0.7103 -0.11164297 0.7059 -1.269018275 
51 0.7122 0.15543387 0.7142 -0.092131056 
52 0.7078 -0.46524442 0.7206 0.79683597 
53 0.7078 -0.46524442 0.72 0.714166667 
54 0.7099 -0.16805184 0.7086 -0.883149873 
55 0.698 -1.87578797 0.7112 -0.514341957 
56 0.7107 -0.05529759 0.716 0.159497207 
57 0.705 -0.86425532 0.7233 1.16715056 
58 0.7092 -0.26692047 0.7081 -0.954384974 
59 0.7083 -0.39432444 0.7113 -0.500210881 
60 0.7089 -0.30935252 0.7288 1.913007684 
61 0.7219 1.49702175 0.7111 -0.528477007 
62 0.7124 0.18346435 0.711 -0.542616034 
63 0.7123 0.16945107 0.7031 -1.672308349 
64 0.7146 0.49076406 0.7042 -1.513490486 
65 0.7192 1.12722469 0.7124 -0.345030882 
66 0.7054 -0.80705982 0.7106 -0.599211934 
67 0.7153 0.58814483 0.7044 -1.484667802 
68 0.711 -0.01308017 0.7095 -0.755179704 
69 0.7094 -0.23865238 0.7065 -1.183014862 
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70 0.7068 -0.6073854 0.7059 -1.269018275 
71 0.7157 0.64370546 0.7133 -0.218421422 
72 0.7144 0.46290594 0.7072 -1.082861991 
51.1987 51.4698 
Av. Wt. 0.711093 0.714858 
S.D 0.004412 0.006055 
APPENDIX 8 STANDARD OPERATING PROCEDURES FOR ASSAY OF THE 
ANTIHYPERTENSIVE DRUG PRODUCTS (The British Pharmacopoeia 2001 
Procedures) 
A. ATENOLOL 
1. Powder 20 tablets. 
2. Transfer the powder to a 500-m1 flask using 300 ml of methanol 
3. Heat the resulting suspension to 60° and shake for 15 minutes. 
4. Cool, dilute to 500 ml with methanol 
5. Filter through a fine glass micro-fibre filter paper (Whatman GF/C is suitable) 
6. Dilute a suitable volume of the filtrate with sufficient methanol to produce a solution containing 
0.0 1% w/v of Atenolol. 
7. Measure the absorbance of the resulting solution at the maximum at 275 rim, Appendix II B. 
8. Calculate the content of C14H22N203 taking 53.7 as the value of A (1%, 1 cm) at the maximum at 
275 nm. 
9. Repeat the procedures in 1 to 8 twice 
10. Calculate the average and standard deviation of the determination 
B. FUROSEMIDE 
1. Weigh and powder 20 tablets. 
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2. Shake a quantity of the powder containing 0.2 g of Furosemide with 300 ml of 0.1M sodium 
hydroxide for 10 minutes 
3. Add sufficient 0.1M sodium hydroxide to produce 500 ml and filter 
4. Dilute 5 ml to 250 ml with 0.1M sodium hydroxide 
5. Measure the absorbance of the resulting solution at the maximum at 271 nm, Appendix II B.(BP 
2001) 
6. Calculate the content of C12H 11C1N205S taking 580 as the value of A(1%, 1 cm) at the maximum 
at 271 nm. 
7. Repeat the procedures in 1 to 8 twice 
8. Calculate the average and standard deviation of the determination 
C. METHYLDOPA TABLETS 
1. Weigh and powder 20 tablets. 
2. Dissolve a quantity of the powder containing the equivalent of 0.1 g of anhydrous methyldopa as 
completely as possible in sufficient 0.05M sulphuric acid to produce 100 ml and filter. 
2. To 5 ml of the filtrate add 2 ml of iron (II) sulphate-citrate solution, 8 ml of glycine buffer 
solution and sufficient water to produce 100 ml. 
3. Measure the absorbance of the resulting solution at the maximum at 545 nm, Appendix II B. 
4. Repeat the procedure using 5 ml of a 0.10% w/v solution of methyldopa BPCRS in place of 5 ml 
of the filtrate, beginning at the words 'add 2 ml of...' 
5. Calculate the content of C10H13NO4 using the declared content of C10H13NO4 in methyldopa 
BPCRS. 
6. Repeat the procedures in 1 to 8 twice 
7. Calculate the average and standard deviation of the determination 
** IRON(II) SULPHATE-CITRATE SOLUTION (Prepare immediately before use) 
1. Dissolve 1 g of sodium metabisulphite in 200 ml of water 
1. Add: 
a. 0.5 ml of 2M hydrochloric acid 
b. 1.5 g of iron(II) sulphate and 
c. 10 g of sodium citrate. 
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**GLYCINE BUFFER SOLUTION 
1. Mix 42 g of sodium hydrogen carbonate and 50 g of potassium hydrogen carbonate 
with 180 mL of water 
2. Add a solution containing 37.5 g of Glycine and 15 mL of 13.5 M ammonia in 180 
mL of water 
3. Dilute to 500 mL with water and stir until solution is complete. 
D. ASSAY OF CAPTOPRIL TABLETS 
1. Weigh and powder 20 tablets. 
2. Carry out the method for liquid chromatography, Appendix III D, using the following 
solutions. 
a. For solution (1) transfer a quantity of the powdered tablets containing 25 mg of Captopril 
to a centrifuge tube 
b. Add 25 ml of the mobile phase 
c. Mix with the aid of ultrasound for 15 minutes and centrifuge. 
d. Dilute 1 volume of the supernatant liquid to 10 volumes with the mobile phase. Solution 
(2) contains 0.01% w/v of captopril BPCRS and 0.0005% w/v of captopril disulphide 
BPCRS in the mobile phase. 
3. For chromatographic procedure, use: 
4. (a) a stainless steel column (25 cmx4.6 mm) packed with stationary phase C (10 µm) 
(Nucleosil C18 is suitable) 
5. (b) a mixture of 0.5 volume of orthophosphoric acid, 450 volumes of water and 550 volumes 
of methanol as the mobile phase 
(c) a flow rate of I ml per minute and 
(d) a detection wavelength of 220 nm. 
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The test is not valid unless, in the chromatogram obtained with solution (2), the resolution factor 
between the peaks due to captopril and captopril disulphide is at least 2.0. 
Calculate the content of CgH15N03S using the declared content of C9H15NO3S in captopril BPCRS. 
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